snapIoT has announced a successful integration of its mClinical platform, snapClinical, with ActiGraph’s CentrePoint System. This integration aims to give Sponsors and CROs improved power in data collection and insights for clinical trials.
ActiGraph’s medical-grade wearables and cloud-based data management platform provide a modern solution for collecting and delivering objective data points in real-time. These validated measurements provide insight into activity intensity, steps, energy expenditure, sleep time, and sleep efficiency. snapIoT’s mClinical platform delivers patient-centric mobile solutions to facilitate the collection of surveys and ePROs (electronic Patient Reported Outcomes) as well as monitor the daily operations of decentralized clinical trials. The COVID-19 crisis has made clear the need to leverage digital technologies to sustain clinical trials and protect the health of patients when normal trial operations are interrupted. The combination of digital patient monitoringalong with smart sensors provides safe methods to continue data collection via virtual outlets.
The data collected from ActiGraph’s wearables uploads to the Cloud where snapClinical can securely retrieve and store the data. With different types of measurements being collected through the sensors, snapIoT makes visualizing data simple by creating graphs that have the flexibility to overlay data points. snapClinical also allows users to easily compare these data points with other types of collected measurements, such as surveys and diaries. Sponsors and CROs can get insight into patients and ensure that they are engaged and compliant with the study protocol.
With the technology of snapIoT and ActiGraph, the integration between the two companies was accomplished in less than a week. The connectivity also makes it easy for newly validated algorithms to be implemented into the system as updates or other requirements are added. The integration provides simplistic efficiencies as the sensors are implemented directly into the snapClinical workflow engine. The power of snapIoT’s workflow engine ensures that the integration can be quickly deployed into new study protocols with minimal effort.
“We continue to drive more wearable and sensor integrations into our snapClinical platform in record timelines to fully support decentralized clinical trials. Our partnership with ActiGraph brings an industry integration to Sponsors and CROs offering a greater ability to quickly deliver a patient-centric experience,” said Isaac Eteminan, CEO of snapIoT.
“We were very impressed with snapIoT’s ability to quickly develop a platform integration to address our mutual customers’ requirements. As digital endpoints have become more prevalent, we know that providing contextual insights into patient behavior in tandem with objective sensor data is crucial in establishing the baseline for our pharma clients to make definitive regulatory claims. We’re excited about future opportunities with snapIoT, and this integration is a great start,” said Jeremy Wyatt, President & COO of ActiGraph.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.